// App-Quantinova.ai

: Effect of Therapeutic-Dose Heparin on Acute Kidney Injury in Non-Critically Ill Hospitalized Patients With Covid-19 The Activ4a and Attac Randomized Trial

Researchers

Presenter

  • Nathaniel Smilowitz

Principal Investigators

  • Erinn Hade

  • Lucy Kornblith

  • Lana Castellucci

  • Mary Cushman

  • Michael E Farkouh

  • Beverly Hunt

  • Keri Kim

  • Andrei Kindzelski

  • Patrick R Lawler

  • Eric Leifer

  • Bryan J McVerry

  • Harmony Reynolds

  • Judith Hochman

  • Judith S Hochman

  • Matthew D Neal

  • Jeffrey S Berger

Medical Centers

  • San Francisco, CA

  • Sch of Epidemiology and Public Health, Univ of Ottawa, Canada

  • NYU Grossman Sch Of Medicine, New York, NY

  • NYU Grossman Sch Of Medicine, New York, NY

  • University of Illinios at Chicago, Chicago, IL

  • New York Univ Sch of Med, New York, NY

  • PETER MUNK CARDIAC CENTRE, Toronto, Canada

  • ICAHN SCHOOL OF MEDICINE MOUNT SINA, New York, NY

  • University of Pittsburgh, Pittsburgh, PA

  • Medicine, Univ of Vermnt, Burlington, VT

  • Kings College London, London, United Kingdom

  • Peter Munk Cardiac Centre, Toronto, Canada

  • NYU Grossman Sch of Medicine, NY

  • ICAHN SCHOOL OF MEDICINE MOUNT SINA, New York, NY

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Infectious Diseases (ID)

Disease

  • Acute renal failure

  • Renal disease

  • Coronavirus disease

Biomarkers

  • Creatinine

  • D-dimer

Drug/Treatment

  • Heparin

  • Epoch

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved